Dupuytren Contracture - Pipeline Insight, 2025

This “Dupuytren Contracture - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Dupuytren Contracture pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Dupuytren Contracture: Understanding

Dupuytren Contracture: Overview

Dupuytren's contracture, also known as Dupuytren's disease, is a fibroproliferative disorder characterized by the thickening and shortening of the palmar fascia, leading to disabling contractures of the fingers. This condition primarily affects the ring and little fingers and is more prevalent in males, particularly those of Northern European descent, typically between the ages of 40 and 80. The exact etiology of Dupuytren's contracture remains largely unknown, although genetic predisposition plays a significant role, with environmental risk factors such as diabetes, alcoholism, and manual labor being commonly associated with its development. While the progression of the disease is slow, it can lead to significant functional impairment over time. The disease typically progresses through several stages, beginning with the formation of painless nodules in the palm, which eventually evolve into fibrous cords. These cords can cause fixed flexion deformities at the metacarpophalangeal and proximal interphalangeal joints, severely limiting hand mobility and dexterity. In some cases, the condition can lead to an inability to fully extend the affected fingers. Early diagnosis and appropriate management are crucial to slow disease progression and preserve hand function, with treatments ranging from conservative therapies to surgical intervention in more advanced stages.

The etiology of Dupuytren's contracture is complex and multifactorial, with genetic predisposition playing a central role in its development. It is primarily inherited as an autosomal dominant trait, meaning that individuals with a family history of the disease are more likely to develop it themselves. Research has shown that individuals of Northern European descent are particularly at risk, with studies revealing a significant sibling recurrence-risk ratio, highlighting the hereditary nature of the condition. Along with genetic factors, environmental triggers such as diabetes, smoking, and alcohol consumption are known to contribute to both the onset and progression of the disease. The underlying pathophysiology involves abnormal fibroblast proliferation and excessive collagen deposition in the palmar fascia, leading to the formation of thickened nodules and cords that cause finger flexion deformities. Some theories also suggest that microvascular ischemia, possibly resulting from trauma or repetitive stress, may play a role in initiating the disease by stimulating myofibroblast activity and collagen buildup.

The clinical presentation of Dupuytren's contracture is marked by a slow and progressive onset of symptoms that usually develop over a period of several years. The condition commonly begins with the formation of small, painless nodules in the palm, most often near the ring and little fingers. These nodules may initially be tender to the touch but typically become painless as the disease progresses. Over time, the nodules transform into thickened cords of fibrous tissue, which can extend into the fingers, causing contractures at the metacarpophalangeal and proximal interphalangeal joints. As a result, the affected fingers are gradually pulled toward the palm, leading to fixed flexion deformities that severely limit hand function, making tasks such as gripping, writing, or shaking hands difficult. Dupuytren's contracture often affects both hands, though one hand is typically more severely involved than the other.

The management and treatment of Dupuytren's contracture are tailored to the severity of the condition and the level of functional impairment experienced by the patient. In the early stages of the disease, non-surgical treatments may be recommended to manage symptoms and maintain hand function. These may include corticosteroid injections to reduce pain and inflammation associated with the nodules, as well as physical therapy to help maintain flexibility and prevent stiffness. However, it is important to note that these treatments do not halt disease progression. As Dupuytren's contracture advances, surgical interventions are often necessary to address more significant deformities. The most common surgical options include fasciectomy, in which the thickened palmar fascia is surgically removed to restore finger mobility, and needle aponeurotomy, a less invasive technique that uses a needle to divide the fibrous cords without the need for extensive surgery.

"Dupuytren Contracture- Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dupuytren Contracture pipeline landscape is provided which includes the disease overview and Dupuytren Contracture treatment guidelines. The assessment part of the report embraces, in depth Dupuytren Contracture commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dupuytren Contracture collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dupuytren Contracture R&D. The therapies under development are focused on novel approaches to treat/improve Dupuytren Contracture.

Dupuytren Contracture Emerging Drugs Chapters

This segment of the Dupuytren Contracture report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dupuytren Contracture Emerging Drugs

VEN 201: Ventoux Biosciences, Inc.

VEN-201 Is an investigational compound which demonstrated key anti-fibrotic actions and a positive safety profile in a pre-clinical in vivo study using an established dermal fibrosis (scleroderma) model. Based on the demonstrated anti-fibrotic effects the company is working to advance VEN-201 as the lead developmental candidate targeting Dupuytren’s and Ledderhose disease. Based upon the pre-clinical evaluation of VEN-201 as a potential anti-fibrotic agent, the company is working to advance the compound as a repurposed, reformulated, disease modifying agent with a novel route of administration, via an expedited regulatory pathway. Currently, the drug is in Preclinical stage of its development for the treatment of Dupuytren’s syndrome.

Dupuytren Contracture: Therapeutic Assessment

This segment of the report provides insights about the different Dupuytren Contracture drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dupuytren Contracture

• There are approx. 2+ key companies which are developing the therapies for Dupuytren Contracture. The companies which have their Dupuytren Contracture drug candidates in the most advanced stage, i.e. Preclinical include, Ventoux Biosciences, Inc.

Phases

The report covers around 2+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dupuytren Contracture pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dupuytren Contracture: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dupuytren Contracture therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dupuytren Contracture drugs.

Dupuytren Contracture Report Insights

• Dupuytren Contracture Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dupuytren Contracture Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dupuytren Contracture drugs?
• How many Dupuytren Contracture drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dupuytren Contracture?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dupuytren Contracture therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dupuytren Contracture and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• 180 Life Sciences
• Ventoux Biosciences, Inc.

Key Products

• Adalimumab
• VEN 201

This product will be delivered within 2 business days.